Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

Philip Stevens, a 66-year-old from Hampshire, has received £70,000 from his GP following a lawsuit after he was given the ...

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Parkinson's affects more than 1 million people in the US. Only 10 to 20% of people with Parkinson's experience symptoms ...

Annovis Bio, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Their primary product, ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...